Il-17F level or predictable ef

United States academics found that relapse ease multiple sclerosis (RRMS) patients, Beta Interferon (IFN-beta) no answer may be treated with serum interleukin (IL) higher levels of -17F.　　　The papers published online March 28, 2010 in nature? medicine (Nat Med) magazine. IFN-beta is the main treatment of multiple sclerosis drug, but its effect is not clear.　　　Therefore, researchers in experimental autoimmune encephalomyelitis (EAE) in animal models and in patients with RRMS for evaluation. Results showed that IFN-β can be effective in reducing the secondary t-cell (TH) 1-induced EAE related symptoms, and effects associated with TH1 EAE spleen cells induced by IL-10 added. But TH17 cells in EAE, IFN-beta put pressure condition, without changing IL-10 standard but can reduce IL-17 to generate, however produces no therapeutic benefits. The researchers also found that the inhibition induced by IL-17 and IL-10 are dependent on the gamma interferon (IFN-γ). When you lack IFN-gamma signal transduction, IFN-beta on EAE is invalid. In RRMS patients, serum IL-17F concentrations above IFN-beta no answer of respondent. Compared with the respondent, no answer of the corticosteroid dosage is bigger, higher recurrence rates. www.cmt.com.cn